Acute Lymphoid Leukemia Clinical Trials

8 recruiting

Frequently Asked Questions

Common questions about Acute Lymphoid Leukemia clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 114 of 14 trials

Recruiting
Phase 2

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

LymphomaMyelofibrosisAML (Acute Myelogenous Leukemia)+8 more
Center for International Blood and Marrow Transplant Research358 enrolled13 locationsNCT06859424
Recruiting
Phase 1Phase 2

CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

Acute Lymphoblastic LeukemiaLymphoma, Non-HodgkinB-cell Lymphoma+8 more
National Cancer Institute (NCI)126 enrolled1 locationNCT05442515
Recruiting
Phase 1

UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1

Acute Lymphoblastic LeukemiaAcute Lymphoid Leukemia
University of Colorado, Denver29 enrolled1 locationNCT05535855
Recruiting
Not Applicable

Clinical Trial of CD19 and CD22 CAR Sequential Therapy Versus Single CD19 CAR Bridging to HSCT for r/r B-ALL Patients

Acute Lymphoblastic Leukemia, in RelapseB-cell Acute Lymphoblastic LeukemiaRefractory Acute Lymphoid Leukemia
Beijing GoBroad Hospital353 enrolled1 locationNCT06343090
Recruiting
Not Applicable

CIK Cell Therapy for Relapsed or Refractory Acute B-Lymphoblastic Leukemia: Prognostic Impact on Patients With Early CAR-T Cell Dysfunction

Acute Lymphoblastic Leukemia, in RelapseB-cell Acute Lymphoblastic LeukemiaRefractory Acute Lymphoid Leukemia
Beijing GoBroad Hospital213 enrolled1 locationNCT06389305
Recruiting
Phase 1

A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)

Refractory Acute Lymphoblastic LeukemiaPhiladelphia-Negative ALLPhiladelphia-Positive ALL+3 more
Memorial Sloan Kettering Cancer Center18 enrolled7 locationsNCT06287528
Recruiting
Phase 1Phase 2

Tafasitamab (MOR00208) in Pediatric Patients With Relapsed or Refractory Acute B Lineage Leukemia

ALL, Childhood B-CellAcute Lymphoid Leukemia RelapseAcute Lymphocytic Leukemia Refractory
University Hospital Tuebingen20 enrolled11 locationsNCT05366218
Recruiting
Phase 1

Phase I Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT

Acute Myeloid LeukemiaMyelodysplastic SyndromesMixed Phenotype Acute Leukemia+1 more
Stanford University24 enrolled1 locationNCT06551584
Recruiting
Phase 1Phase 2

Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)

Acute Myeloid LeukemiaMixed Phenotype Acute LeukemiaAcute Lymphoid Leukemia+4 more
University of Florida40 enrolled4 locationsNCT05322850
Recruiting
Not Applicable

Study of the Medullary Microenvironment in Acute Childhood Leukemia

Acute Myeloid Leukemia in ChildrenAcute Lymphoid Leukemia
University Hospital, Tours40 enrolled3 locationsNCT05792007
Recruiting
Phase 2

Evaluation of Treatment Efficacy According to Risk Group in Relapsed Childhood Acute Lymphoblastic Leukemia

Acute Lymphoid Leukemia
Ho Joon Im90 enrolled7 locationsNCT05827549
Recruiting

Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil

Chemotherapeutic ToxicityMinimal Residual DiseaseGene Abnormality+1 more
Instituto do Cancer do Estado de São Paulo180 enrolled1 locationNCT05959720
Recruiting
Phase 2

Phase II Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia

Acute Lymphoid Leukemia
Institute of Hematology & Blood Diseases Hospital, China21 enrolled1 locationNCT06427330
Recruiting
Phase 2

Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning

Hodgkin LymphomaNon-Hodgkin LymphomaMultiple Myeloma+7 more
University of Liege114 enrolled10 locationsNCT03852407